Lipum AB (publ) (STO:LIPUM)
Sweden · Delayed Price · Currency is SEK 13.95
+0.05 (0.36%)
Feb 5, 2026, 4:31 PM CET
Lipum AB Company Description
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.
The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases.
It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.
The company was incorporated in 2010 and is based in Umeå, Sweden.
Lipum AB (publ)
| Country | Sweden |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Ola Sandborgh |
Contact Details
Address: TvistevAegen 48C Umeå, 907 36 Sweden | |
| Phone | 46 9 03 40 34 30 |
| Website | lipum.se |
Stock Details
| Ticker Symbol | LIPUM |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015660899 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ola Sandborgh | Chief Executive Officer |
| Prof. Olle Hernell M.D. | Co-Founder and Director |
| Associate Prof. Susanne Lindquist | Co-Founder, Head of Research and Chief Scientific Officer |
| Tobias Helgesson | Chief Financial Officer |
| Dr. Pernilla Abrahamsson | Chief Operating Officer |
| Dr. Peter Hovstadius | Chief Medical Officer |